ED50 and ED95 of Remimazolam Tosilate Combined with Different Doses of Fentanyl in Elderly Patients for Painless Gastroscopy
Yanxia Guo,Zhihua Yao,Yan Feng,Dan Wang,Yizheng Wang,Jingyan Lin
DOI: https://doi.org/10.2147/dddt.s462607
IF: 4.3188
2024-06-19
Drug Design Development and Therapy
Abstract:Yanxia Guo, &ast Zhihua Yao, &ast Yan Feng, Dan Wang, Yizheng Wang, Jingyan Lin Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jingyan Lin, Email Background: The novel short-acting benzodiazepine drug, remimazolam tosilate, has been employed for sedation during endoscopic procedures. The optimal loading dosage of remimazolam tosilate in gastroscopy for elderly patients when co-administered with fentanyl remains unclear. Therefore, the primary objective of our research was to ascertain the median effective dose (ED50) and the 95% effective dose (ED95) of remimazolam tosilate in combination with various fentanyl dosages for elderly patients undergoing painless gastroscopy. Methods: Seventy-five patients aged ≥ 65 years and American Society of Anesthesiologists (ASA) class I–III were recruited to undergo elective painless gastroscopy. All patients were randomized assigned to group F 1 , group F 2 , and group F 3 , and were injected intravenously with different doses of fentanyl (0.5 ug/kg, 1 ug/kg, and 1.5 ug/kg) 3 minutes prior to the administration of remimazolam tosilate, respectively. The initial preset dose of remimazolam tosilate was 0.3 mg/kg in group F 1 , 0.2 mg/kg in group F 2 , 0.15 mg/kg in group F 3 . The dose gradient was 0.02 mg/kg per group according to the up-and-down sequential method. Probibt regression model was employed to determine the ED50 and ED95 of remimazolam tosilate. Results: The ED50 of remimazolam tosilate in group F 3 was lower than that in group F 1 and F 2 (0.095 [0.088– 0.108] mg/kg vs 0.162 [0.153– 0.171] mg/kg; 0.258 [0.249– 0.266] mg/kg, p < 0.05). The ED95 of remimazolam tosilate was 0.272 mg/kg (95% CI: 0.264– 0.295 mg/kg) in group F 1 , 0.175 mg/kg (95% CI: 0.167– 0.200 mg/kg) in group F 2 and 0.109 mg/kg (95% CI: 0.101– 0.135 mg/kg) in group F 3 . The total dosage of remimazolam tosilate decreased gradually with the increasing of fentanyl ( p < 0.001). The frequency of injection pain was higher in group F 1 compared to groups F 2 and F 3 ( p < 0.05). The patients in group F 3 had a lower incidence of hypotension than in groups F 1 and F 2 ( p < 0.05). There was no respiratory depression, intraoperative consciousness, dizziness or delirium in the three groups. Conclusion: The concurrent use of fentanyl reduces the dosage of remimazolam tosilate required for sedative gastroscopy in elderly patients in a dose-dependent manner. Moreover, 1.5 ug/kg fentanyl combined with remimazolam tosilate may reduce the incidence of hypotension and injection pain. These findings should be confirmed in a large-scale study. Keywords: painless gastroscopy, elderly patients, median effective dose, fentanyl, remimazolam tosilate The use of gastrointestinal endoscopy is considered the gold standard for both diagnosing and treating upper gastrointestinal diseases. 1 The number of elderly adults undergoing gastroscopy is increasing yearly due to the aging population and advancements in gastrointestinal endoscopy technology. 2 Procedural sedation during gastroscopy can elleviate patients'pain, anxiety, vomit, and discomfort. 3 Although procedural sedation is considered safe in the majority of patients, elderly patients who receive procedural sedation have an increased risk of respiratory depression, 4 hemodynamic instability, 5 arrhythmias, 6 and delayed discharge 7 due to the use of certain sedative agents, such as propofol. Therefore, it is crucial for clinicians to select safe and efficient medications for gastroscopy in elderly patients. However, the use of sedative medications in elderly patients during gastroscopy remains controversial. The newly developed remimazolam tosilate is a short-acting agonist of the gamma-aminobutyric acid A (GABAA) receptor, which effectively inhibits neuronal electrical activity by binding to GABA receptors and induces sedation. 8,9 It is rapidly hydrolyzed by hepatic esterases to inactive carboxylic acid metabolites. 10 In comparison to conventional benzodiazepine sedative medications, remimazolam tosilate has a quicker onset and elimination, milder respiratory and circulatory depression, and fewer adverse effects. 11–13 The safety and efficacy of remimazolam tosilate as a medication for procedural sedation in elderly patients have been demonstrated by several studies. 14– -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal